Le Lézard
Classified in: Covid-19 virus
Subject: Sales

IGNITE's October Sales Exceeded Third Quarter Sales

IGNITE International Brands, Ltd. (CSE:BILZ, OTCQX: BILZF) ("IGNITE" or the "Company"), a global consumer packaged goods company, today announced that sales in the month of October alone exceeded all of third quarter sales.

The performance is a direct result of Ignite's international expansion. Ignite's high quality products made a strong debut in South America and Eastern Europe, positioning Ignite for steady, ongoing growth in these markets. Ignite also plans to expand into the Middle East, Africa, Western Europe and Asia in 2022.

Dan Bilzerian, CEO at IGNITE, states, "As mentioned in a press release last month, Ignite's third quarter sales were the highest in the history of the company, which was yet another quarter of record sales. We are now pleased to report that sales in the month of October alone have exceeded all of Q3 sales. I am confident that, based on October sales and recently secured contracts, fourth quarter sales will exceed the sales for all three prior quarters combined."


IGNITE is a global consumer premium brand, operating in several market segments. IGNITE product categories include CBD products, nicotine and synthetic nicotine vape products, premium performance drinks named ZRO, apparel, and spirits featuring tequila and a premium vodka.

Shares of IGNITE are listed on the Canadian Securities Exchange (CSE) under the symbol "BILZ" and quoted in the United States on the OTCQX under the symbol "BILZF".

Further information on IGNITE can be found on the Company's website at www.ignite.co.


This news release includes certain "forward?looking statements" under applicable Canadian securities legislation. Forward?looking statements are necessarily based upon several estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward?looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the effects and impacts of the coronavirus disease (COVID?19) pandemic, the extent and duration of which are uncertain at this time on IGNITE's business, and general economic and business conditions. There can be no assurance that any of the forward?looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward?looking statements. The Company disclaims any intention or obligation to update or revise any forward?looking statements, whether because of new information, future events or otherwise, except as required by law.

These press releases may also interest you

at 14:05
Griffon Corporation ("Griffon" or the "Company") has successfully completed its previously announced acquisition of Hunter Fan Company ("Hunter Fan" or "Hunter"), the leading U.S. brand of residential ceiling fans for $845 million, subject to...

at 14:00
The "Global Recommendation Engine Market Size, Share & Trends Analysis Report by Type (Collaborative Filtering, Hybrid Recommendation), by Deployment, by Application, by Organization, by End-use, by Region, and Segment Forecasts, 2021-2028" report...

at 14:00
Evolent Health, Inc. , a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced that it has partnered with a minority-owned business, PCG Consulting Group (PCG), to launch a new...

at 13:55
Community Heritage Financial, Inc. ("the Company") , the parent company for Middletown Valley Bank ("MVB" or the "Bank") and Millennium Financial Group, Inc. ("Mlend"), announced today that for the period ending December 31, 2021 the Company earned...

at 13:30
According to Coherent Market Insights, the global trypsin market is estimated to be valued at US$ 42.95 million in 2021 and is expected to exhibit a CAGR of 4.3% during the forecast period (2021-2028). Key Trends and Analysis of the Global Trypsin...

at 13:30
AIkido Pharma Inc. ("AIkido" or the "Company"), a clinical and early-stage drug development company, today announced that its board of directors (the "Board") has authorized a share repurchase program to repurchase up to $3 million of the Company's...

News published on 3 november 2021 at 08:10 and distributed by: